Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 19/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15647777 | 0.89 | RORC (0.66) | RORCMEN1LMNACYP2D6HRH1 | |
| SCHEMBL16645264 | 0.87 | RORC (0.52) | RORCMEN1LMNACYP2D6HRH1 | |
| SCHEMBL16632156 | 0.87 | RORC (0.49) | RORC | |
| SCHEMBL22726340 | 0.86 | RORC (0.39) | RORCMEN1LMNACYP2D6HRH1 | |
| SCHEMBL16641742 | 0.85 | RORC (0.57) | RORC | |
| SCHEMBL18099724 | 0.85 | RORC (0.46) | RORCMEN1LMNACYP2D6HRH1 | |
| Trifluoroacetic Acid SCHEMBL22710585 | 0.83 | RORC (0.54) | RORC | |
| SCHEMBL16632049 | 0.82 | RORC (0.48) | RORC | |
| SCHEMBL15648845 | 0.82 | MEN1 (0.50) | RORCMEN1LMNACYP2D6HRH1 | |
| SCHEMBL16459612 | 0.79 | RORC (0.62) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057950-B1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-02 | — | — | EP | disclosed |
| EP-3057950-B1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-02 | — | — | EP | disclosed |
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-20160279122-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-29 | — | — | US | disclosed |
| US-20160279122-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-29 | — | — | US | disclosed |
| US-20160279122-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-29 | — | — | US | disclosed |
| EP-3057950-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2016-08-24 | — | — | EP | disclosed |
| US-9403816-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-02 | — | — | US | disclosed |
| US-9403816-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-02 | — | — | US | disclosed |
| US-9403816-B2 | Phenyl linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-02 | — | — | US | disclosed |
| WO-2015057203-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105404-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105404-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105404-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279122-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORgammat | RORC, RORB, RORA | RORC 1/4885MEN1 4518/4885LMNA 4083/4885 |
| US-10369146-B2 | Phenyl linked quinolinyl modulators of RORγt | RORC, RORB, RORA | RORC 1/4885MEN1 4510/4885LMNA 4186/4885 |
| US-20150105404-A1 | PHENYL LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | RORC 1/4885MEN1 4667/4885LMNA 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.